Director Declaration


22 September 2016 11.00

New external board appointment

Listing Rule LR 9.6.14 R (2)

Ann Cairns, a Non-Executive Director of AstraZeneca PLC, is expected to join the
Board of Directors of Intercontinental Exchange, Inc., a company listed on the
New York Stock Exchange, effective from 2017.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas - Respiratory and
Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company
is also active in inflammation, infection and neuroscience through numerous
collaborations. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Neil Burrows         UK/Global                            +44 203 749 5637
Vanessa Rhodes       UK/Global                            +44 203 749 5736
Karen Birmingham     UK/Global                            +44 203 749 5634
Rob Skelding         UK/Global                            +44 203 749 5821
Jacob Lund           Sweden                               +46 8 553 260 20
Michele Meixell      US                                   +1 302 885 2677
Investor Relations
UK
Thomas Kudsk Larsen                                       +44 203 749 5712
Craig Marks          Finance, Fixed Income, M&A           +44 7881 615 764
Nick Stone           Respiratory & Autoimmunity           +44 203 749 5716
Henry Wheeler        Oncology                             +44 203 749 5797
Christer Gruvris     Infection & Neuroscience             +44 203 749 5711
US
Lindsey Trickett     Cardiovascular & Metabolic Diseases  +1 240 543 7970
Mitchell Chan         Oncology                            +1 240 477 3771
Toll-free                                                 +1 866 381 7277

Adrian Kemp

Company Secretary

AstraZeneca PLC

-ENDS-

Attachments

09225989.pdf